Aryeh Sand is a Managing Director in Healthcare, focused on the specialty and generic pharma, nuclear medicine, contrast media and diagnostic imaging spaces. He joined the firm in 2022.
Aryeh has 12+ years of healthcare investment banking experience and specializes in advising clients in the specialty and generic pharma, nuclear medicine, contrast media and diagnostic imaging spaces. He has advised boards of directors and special committees as well as companies on a broad range of transactions, including mergers, acquisitions, divestitures, leveraged buyouts, restructurings and capital raising solutions.
Prior to joining Solomon Partners, Aryeh was a Managing Director and Head of Healthcare Investment Banking at TAP Advisors where he spent six years building the firm’s healthcare effort. Prior to TAP, Aryeh was a founding member and senior banker in Mizuho’s Healthcare Investment Banking group. Over the past decade, Aryeh has advised or has served as a lead financing banker on numerous key healthcare transactions with a total transaction value of over $100 billion. Aryeh has worked with leading companies such as Actavis / Allergan, Amgen, Gilead, Mallinckrodt Nuclear Medicine, Azurity Pharmaceuticals, Upsher-Smith, Alora Pharmaceuticals, and BWXT Medical.
Aryeh earned an Honours B.Comm degree from the University of Toronto.